Kevin McNamara, MD
Gastroenterology · Tulsa, OKNPI 1770744575
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 567 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,062, 2.1 times the $1,000 reported in 2019.
Across 567 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$953
- Pfizer$615
- Regeneron Healthcare Solutions, Inc.$333
- plus $3K from 29 others
Across 53 payments — averaging $4019.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$185K
- Intercept Pharmaceuticals, Inc.$28K
What the payments were for
- Food & beverage$9,77299%
- Education$100%
- Entertainment$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 153 | $2,325 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 98 | $1,517 |
| Takeda Pharmaceuticals U.S.A., Inc. | 62 | $1,250 |
| Johnson & Johnson | 58 | $953 |
| Pfizer | 34 | $615 |
| Regeneron Healthcare Solutions, Inc. | 15 | $333 |
| Gilead | 16 | $297 |
| Bristol Myers Squibb | 15 | $277 |
| Ferring Pharmaceuticals Inc. | 16 | $276 |
| Lilly USA, LLC | 10 | $246 |
| Olympus America Inc. | 12 | $203 |
| Ipsen Biopharmaceuticals, Inc | 9 | $157 |
| Sanofi | 9 | $149 |
| Aimmune Therapeutics, Inc. | 4 | $128 |
| Braintree Laboratories, Inc. | 7 | $120 |
| Boston Scientific | 1 | $117 |
| Daiichi Sankyo Inc. | 5 | $109 |
| QOL Medical, LLC | 6 | $104 |
| Merck | 6 | $96 |
| Medtronic | 2 | $83 |
| Mauna Kea Technologies, Inc. | 2 | $72 |
| Madrigal Pharmaceuticals | 3 | $72 |
| Ironwood Pharmaceuticals, Inc | 4 | $60 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| Ardelyx, Inc. | 2 | $42 |
| Biocon Biologics Inc | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $28 |
| Boehringer Ingelheim | 2 | $26 |
| Amgen | 2 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Organon | 2 | $15 |
| Sandoz | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,855 in reported general payments places this provider in the 75th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 76 | $12,528 |
| LinzessLinaclotide | 12 | $11,571 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 72 | $9,672 |
| Dexlansoprazole DrDexlansoprazole | 15 | $6,424 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 38 | $6,104 |
| Budesonide DrBudesonide | 16 | $3,703 |
| Cholestyramine LightCholestyramine | 18 | $2,848 |
| Omeprazole | 121 | $2,504 |
| Pantoprazole Sodium | 100 | $2,035 |
| Sucralfate | 19 | $1,537 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 52 | $959 |
| Ondansetron OdtOndansetron | 16 | $396 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 26 | $395 |
| Dicyclomine Hcl | 16 | $352 |
| Famotidine | 14 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ferring Pharmaceuticals Inc.Clenpiq | $276 | $12,52876 claims |
| AbbVieLinzess | $2,325 | $11,57112 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $1,517 | $9,67272 claims |
| Braintree Laboratories, Inc.Sutab | $120 | $6,10438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 133 gastroenterology providers in Oklahoma.
Other gastroenterology in Tulsa
- Jeffrey HuntTulsa$155K
- Harvey TatumTulsa$27K
- Roy ThompsonTulsa$16K
- Aaron FiekerTulsa$15K
- Vasudevan RaghuramanTulsa$14K
- William BriggsTulsa$14K
- Sheldon BergerTulsa$14K
- David MorrisTulsa$13K
- Patrick VolakTulsa$13K
- Matt BlankenshipTulsa$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.